Description
Zintasa 400 mg Enteric-Coated Tablets
Description
Zintasa 400 mg Enteric-Coated Tablets contain mesalazine (400 mg) and are used to treat mild to moderate ulcerative colitis and maintain remission in ulcerative colitis patients. These tablets are red-brown, round, and enteric-coated.
Therapeutic Indications
Zintasa is indicated for:
– Treating mild to moderate ulcerative colitis.
– Maintaining remission of ulcerative colitis.
Posology and Method of Administration
– **Adults:** Dosage and administration specifics should be determined by a healthcare professional based on the individual patient’s condition.
– **Children:** Not recommended for children under 2 years of age.
Contraindications
– Hypersensitivity to mesalazine or any excipients listed in section 6.1.
– History of sensitivity to salicylates or renal sensitivity to sulphasalazine.
– Confirmed severe renal impairment (GFR less than 20 ml/min).
Special Warnings and Precautions for Use
– Regular monitoring of renal function is advised.
– Caution should be exercised in patients with pre-existing renal impairment or those with conditions that can affect renal function.
Interaction with Other Medicinal Products
– Mesalazine may interact with other medications. Consult your doctor or pharmacist for specific interactions.
Fertility, Pregnancy, and Lactation
– Mesalazine can be used during pregnancy and lactation, but only if the potential benefits outweigh the risks. Consult your healthcare provider.
Effects on Ability to Drive and Use Machines
– Zintasa does not usually affect the ability to drive or operate machinery.
Undesirable Effects
– Common side effects include headache, nausea, and abdominal pain.
– Serious side effects can include renal impairment and hypersensitivity reactions.
Overdose
– In case of overdose, seek medical attention immediately. Treatment is symptomatic and supportive.
Pharmacological Properties
Pharmacodynamic Properties
– Mesalazine (5-aminosalicylic acid) is the active component of sulphasalazine responsible for treating ulcerative colitis. It works by inhibiting the lipoxygenase pathway, which is involved in the formation of leucotrienes that contribute to the pathogenesis of ulcerative colitis.
